**ASX ANNOUNCEMENT** **26 APRIL 2023**

# PHASE 1B MULTI SITE BRAIN CANCER CLINICAL TRIAL APPROVED FOR INITIATION

- New Chimeric Phase 1B clinical trial of CHM 1101 receives approval from ethics review board
- The Phase 1B trial will involve participation of multiple clinical sites

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), the only ASX-listed clinical stage cell therapy company, is pleased to announce that it has received ethics approval for the initiation of a multi-site Phase 1B clinical trial of CHM 1101 in patients with recurrent and/ or progressive glioblastoma multiforme (GBM).

This new chapter in the development of CHM 1101 will see Chimeric leading a two-part Phase 1B clinical study enrolling patients with recurrent and/ or progressive GBM at multiple clinical trial sites.

Part A of the trial will treat 3-6 patients, completing the Phase 1 CHM 1101 dose escalation/ confirmation study that was initiated at City of Hope Cancer Centre.

At the end of 2023, an assessment of clinical safety and efficacy data from the Phase 1 dose escalation/ confirmation cohort will be undertaken. Should the results of that assessment support further development, Part B of the trial design would be initiated.

Part B of the trial is a dose expansion cohort designed to enroll 12-26 patients with recurrent and/ or progressive GBM using the recommended Phase 2 dosing plan and assessing for efficacy and safety.

Upon successful completion of the Part B dose expansion cohort, a registration trial will be initiated in alignment with regulatory feedback.

"Expanding our clinical program to additional sites is critical to our mission to deliver our medicines to the patients who need them," said Dr Jason Litten, Chief Medical Officer of Chimeric Therapeutics. "The two-part trial design also ensures that we are positioned to move rapidly into the dose expansion cohort upon a positive clinical assessment of the Phase 1 data at the end of 2023."

**CHM 1101 PHASE 1A/B Multi-Site Clinical Trial Design**




Additional details on the CHM Phase 1B trial design and objectives are being presented at the American Society of Clinical Oncology (ASCO) annual meeting as part of the Central Nervous System Tumors section on June 3, 2023.

---

**About CHM 1101**:

CHM 1101 (CLTX CAR T) is a first in class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma, patients who have a poor prognosis, with limited treatment options and a median survival of less than 1 year (Gallego. *Curr Oncol*, 2015).

CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom, as the tumour-targeting component of the chimeric antigen receptor (CAR).

In preclinical models, CHM 1101 CAR T cells have been shown to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13.
CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.

CHM 1101 is currently being studied in an ongoing phase 1A clinical trial in recurrent / progressive glioblastoma at City of Hope Cancer Centre in California. Outcomes from the initial two dose levels of the Phase 1A trial have been previously presented and demonstrated patient safety with a disease stability rate of approximately 70%.

**ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, the only ASX listed clinical stage cell therapy company, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes two first in class autologous CAR T cell therapies and a best in class allogeneic NK cell therapy platform. Chimeric assets are being developed across multiple different disease areas in both solid tumours and blood cancers with 2 ongoing clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial.

CHM 2101 (CDH17 CAR T) is a first in class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best in class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform,

Chimeric has initiated development of new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

**CONTACT**


Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au